Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Dec;31(12):1594-1596.
doi: 10.1016/j.annonc.2020.10.001. Epub 2020 Oct 8.

Last but not least: antibody-drug conjugates in hormone receptor-positive metastatic breast cancer

S R Stecklein  1 , P Sharma  2
Affiliations
Editorial

Last but not least: antibody-drug conjugates in hormone receptor-positive metastatic breast cancer

S R Stecklein et al. Ann Oncol. 2020 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosure PS reports research funding (to the institution) from Novartis, Merck, Bristol Meyer Squibb, and Celgene, and consulting relationships with Novartis, Merck, Immunomedics, Seattle Genetics, and Exact Biosciences. SRS has declared no conflicts of interest.

Comment on

References

    1. Andre F, et al., Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. N Engl J Med, 2019. 380(20): p. 1929–1940. - PubMed
    1. Cristofanilli M, et al., Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol, 2016. 17(4): p. 425–439. - PubMed
    1. Kornblum N, et al., Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. J Clin Oncol, 2018. 36(16): p. 1556–1563. - PMC - PubMed
    1. Slamon DJ, et al., Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. J Clin Oncol, 2018. 36(24): p. 2465–2472. - PubMed
    1. Sledge GW Jr., et al., MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol, 2017. 35(25): p. 2875–2884. - PubMed